Cross-reactive bactericidal antimeningococcal antibodies can be isolated from convalescing invasive meningococcal disease patients using reverse vaccinology 2.0
The threat from invasive meningococcal disease (IMD) remains a serious source of concern despite the licensure and availability of vaccines. A limitation of current serogroup B vaccines is the breadth of coverage afforded, resulting from the capacity for extensive variation of the meningococcus and...
मुख्य लेखकों: | Bidmos, F, Nadel, S, Screaton, G, Kroll, J, Langford, P |
---|---|
स्वरूप: | Journal article |
प्रकाशित: |
Frontiers Research Foundation
2018
|
समान संसाधन
-
Cross-Reactive Bactericidal Antimeningococcal Antibodies Can Be Isolated From Convalescing Invasive Meningococcal Disease Patients Using Reverse Vaccinology 2.0
द्वारा: Fadil A. Bidmos, और अन्य
प्रकाशित: (2018-07-01) -
Bacterial Vaccine Antigen Discovery in the Reverse Vaccinology 2.0 Era: Progress and Challenges
द्वारा: Fadil A. Bidmos, और अन्य
प्रकाशित: (2018-10-01) -
The Epidemiological Impact of Antimeningococcal B Vaccination in Cuba
द्वारा: Antonio Pérez Rodríguez, और अन्य
प्रकाशित: (1999-07-01) -
Editorial: Reverse Vaccinology
द्वारा: Richard Moxon, और अन्य
प्रकाशित: (2019-12-01) -
On the controversy about the efficacy of the antimeningococcal B vaccine: methodological pitfalls
द्वारा: Costa Eduardo de A.
प्रकाशित: (1995-01-01)